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Chronic obstructive pulmonary disease (COPD) is 
a common, progressive and preventable disorder of 
the airways. It is often poorly understood by patients, 
and frequently referred to as ‘asthma’ or emphysema, 
which adds to the confusion. It is characterised 
by predominantly fixed airway obstruction as a result of exposure 
to inhaled noxious environmental particles or gases, e.g. cigarette 
smoke, biomass fuels, occupational exposure.[1] The predominant 
symptoms are progressive dyspnoea, cough and wheeze, interlaced 
with periods of acute worsening or so-called exacerbations.
COPD is a prevalent condition (329 million people are affected 
worldwide), with an increasing incidence. Currently, the World Health 
Organization (WHO) ranks COPD as the fourth most important 
cause of death due to non-communicable disease worldwide, which 
is predicted to rise to the third place by 2020.[2] In South Africa 
(SA) there are limited data, but data from Cape Town estimated the 
prevalence to be high (>20%); compared with other countries in the 
BOLD study, Cape Town ranked highest.[3] The population studied 
was not representative of the entire country, and there is no clear 
estimate of how prevalent COPD is. There are also no substantial data 
from the rest of Africa. 
Compared with COPD, asthma, a chronic inflammatory disease 
of the airways, features highly variable airflow obstruction (i.e. 
clinically suggested by a positive bronchodilator response) in most 
cases, leading to episodes of cough, wheeze and dyspnoea, but 
usually with a return to normal baseline lung function between these 
acute ‘attacks’. The focus of this review is the correct diagnosis of 
COPD. It is important to differentiate the condition from asthma 
as the progression of disease, expectation of patient and doctor, and 
management are different. 
It is not always easy to distinguish COPD from asthma because of 
shared clinical features. The term asthma-COPD overlap syndrome 
(ACOS) has been coined to identify this group, which includes 
features of both conditions.[4] It is the subject of much debate and 
beyond the scope of this review, but if in doubt it is considered safer 
to treat the patient as if they are asthmatic. This review focuses on the 
diagnosis and severity evaluation of COPD and relies heavily on the 
South African Thoracic Society Guidelines[5] and the updated GOLD 
strategy document and teaching slides.[1] 
Diagnosis of COPD
A complete history and thorough clinical examination are vital and 
cannot be substituted by any other measure when considering a 
diagnosis of COPD. A progressive decline in respiratory function, 
characterised by dyspnoea or worsening shortness of breath on effort 
(e.g. walking on the level or climbing stairs), cough and wheeze, 
interlaced by periods of intermittent worsening (or exacerbations), 
in a patient with known risk factors is typical for a diagnosis of 
COPD. The disease usually presents after the age of 40 years, with 
a slow progressive onset of symptoms. Importantly, such patients 
generally do not enjoy a full return to normal functioning over a 
period of time, despite treatment (as is the case with asthma). A rapid 
onset of symptoms should raise suspicion of an alternative condition. 
The second key element is a significant exposure history, specifically to 
tobacco smoking – generally >10 pack-years (20 per day for 10 years) – 
for the diagnosis to be considered. If the person started smoking in their 
teenage years, used dagga and/or methaqualone (Mandrax), COPD 
may well occur before the age of 40. One should also enquire about 
additional exposures such as biomass/indoor air pollution, mining 
exposure, previous tuberculosis (TB), HIV, and childhood diseases. 
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Clinical examination is characterised by 
hyperinflation, reduced breath sounds and 
possibly expiratory wheezing. Be certain to 
look for clubbing and lymphadenopathy, 
as the risk of cancer is high in heavy 
smokers. Findings on clinical examination 
often parallel disease severity in advanced 
cases; a myriad of clinical signs might be 
quite obvious (e.g. sarcopenia, pursed-lip 
breathing, a tripod stance, soft-to-absent 
breath sounds), but in the earlier stages there 
might be a paucity of clinical findings. The 
presence of signs of right heart failure/cor 
pulmonale (raised jugular venous pressure, 
hepatomegaly and peripheral oedema) and 
cardiac arrhythmias (e.g. atrial fibrillation) 
should be sought, as these require additional 
management and in most cases prompt 
referral.
A major stumbling block to the correct 
diagnosis of COPD is the requirement for 
spirometry. The use of this technique is 
recognised by international and local 
guidelines; without it a diagnosis cannot 
be confirmed. Airway obstruction is spiro-
metrically defined as the forced expiratory 
volume in 1 second (FEV1)/forced vital 
capacity (FVC) ratio <0.7, with an absolute 
value of FEV1 <80% of predicted for age, 
gender and height. Clinicians are urged 
to refer to the published guidelines on the 
practical use of office spirometry.[6] The 
post-bronchodilator FEV1 is also used to 
grade the severity of obstruction, which is 
important when deciding on management. 
This is percentage-predicted FEV1, not the 
severity of the ratio that is used to grade 
lung function impairment. Lung function 
may help to distinguish a COPD patient 
from one with asthma, but reversibility or 
the lack thereof does not rule out either. 
Lung function must be viewed against the 
clinical picture. Reversibility of >12%/200 mL 
occurred in >50% of patients enrolled in the 
large UPLIFT COPD study, but reversibility 
does not always help to differentiate asthma 
from COPD.[7] 
A chest radiograph may depict features 
of hyperinflation, but does not distinguish 
between asthma and COPD. The value 
of an initial chest radiograph during 
work-up is mainly in screening for 
addition al or alternative lung pathology, 
such as malignancy, parenchymal disease 
(pulmonary fibrosis), or previous TB with 
scarring, but is not a prerequisite to 
start therapy. High-resolution computed 
tomography (HRCT) scanning of the chest 
is excellent for anatomical assessment 
in COPD, as it can precisely locate and 
categorise emphysema. Its use is limited 
by the high cost and lack of general 
availability, and it is not required for the 
diagnosis of COPD in the vast majority 
of cases.
Oxygen saturation or arterial blood gas 
determination is useful in severe disease, 
where respiratory failure is suspected and 
long-term home oxygen is being considered. 
In patients who present very early or have a 
family history of COPD, consider testing for 
alpha-1 antitrypsin deficiency. 
Assessment of severity
COPD and asthma are graded according to 
severity, and management recommendations 
are based on severity categories. Tradition-
ally, management was decided on by lung 
function severity alone, but there has been 
a growing realisation that FEV1 and clinical 
symptoms correlate poorly; therefore, other 
factors are integrated into the severity 
grading. The second conceptual change is 
that severity is ‘graded’ rather than ‘staged’, 
as patients do not necessarily move linearly 
from one stage to another over time.
The South African Thoracic Society 
Guidelines[5] and the GOLD strategy docu-
ment[1] both incorporate assessments of 
FEV1 and dyspnoea; however, the presence 
of exacerbations is prominent in the newer 
GOLD guidelines. We focus on these 
as the most current approach to severity 
assessment. Based on the severity grading, 
appropriate therapy with bronchodilators 
and inhaled steroids (in severe cases) may 
then be instituted. For all grades of severity, 
smoking cessation, structured exercise plans, 
good nutrition and vaccination should be 
considered as part of a holistic treatment plan.
The GOLD ‘square box’ is the focus of the 
assessment and may be daunting at first, but 
once used it is relatively easy (Fig. 1). It is 
easiest to follow a step-wise approach:
1. Assess symptoms and breathlessness 
Either the COPD assessment test (CAT)[8] 
or the modified Medical Research Council 
(mMRC) dyspnoea scale (Fig. 2) may be 
used.[1] Patients can fill in the CAT or mMRC 
form in the waiting room prior to seeing the 
doctor, saving valuable consultation time. 
It also allows for objective assessment of 
symptoms/dyspnoea severity over time. The 
form is available in several local languages. 
For the mMRC the cut-off of ≥2 can be 
simply defined as not being able to keep up 
with a healthy peer. This assessment places 
the patient left or right of the centre line 
(Fig. 1).
2. Evaluate the severity of lung function
In patients with a post-bronchodilator FEV1/
FVC ratio <0.70: 
• GOLD 1: Mild – FEV1 ≥80% predicted  
• GOLD 2: Moderate – FEV1 <80% to ≥50% 
predicted
Fig. 1. Global Initiative for Chronic Obstructive Lung Disease classification of COPD severity. 
Evaluation of symptoms and breathlessness (x-axis), lung function (y-axis, left) and exacerbation 
history (y-axis, right) provides a combined severity assessment upon which to base a treatment 
strategy (CAT = COPD assessment test; mMRC = modified Medical Research Council dyspnoea 
scale; GOLD classification of airflow limitation 1 and 2 FEV1 ≥50% predicted, 3 and 4 FEV1 
<50% predicted). (From the Global Strategy for Diagnosis, Management and Prevention of 
COPD 2015, © Global Initiative for Chronic Obstructive Lung Disease (GOLD), all rights 
reserved.  Available from http://www.goldcopd.org.)
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• GOLD 3: Severe – FEV1 <50% to ≥30% 
predicted
• GOLD 4: Very severe – FEV1 <30% 
predicted.
An FEV1 <50% predicted places a patient in 
a category above the horizontal line.
3. Review the occurrence of exacerbations 
in the past 12 months
An exacerbation is generally considered as 
a worsening of COPD symptoms, resulting 
in treatment with corticosteroids and/or 
antibiotics. More than 2 exacerbations or 
1 exacerbation requiring hospitalisation places 
the patient ‘above the line’. Exacerbations are 
considered more important than lung function 
in the assessment of risk; thus, their presence 
places one above the line even if FEV1 >50% 
predicted. 
4. Evaluate for comorbid diseases such as 
hypertension, heart failure, diabetes
This is not used to place a patient in a box, 
but is important for risk evaluation and 
treatment decisions.
With these elements, the patient can then be 
‘allocated’ to box A, B, C or D. The combined 
assessment therefore takes the following into 
consideration: lung function severity, symptoms 
and exacerbations. The patient should be 
allocated to the highest risk category, e.g. a 
patient with an mMRC >2, plus 2 exacerbations, 
but FEV1 >50%, should be D – not B. For groups 
A and B long-acting bronchodilators are the 
primary treatment option, and for groups C and 
D the addition of inhaled steroids in patients 
with more severe disease.[1]
Assessment of 
comorbidities
Cardiovascular disease contributes to 
the majority of deaths in COPD, despite 
stage or severity, and it is therefore prudent 
that the medical practitioner evaluate all 
patients for cardiovascular risk factors. This 
includes blood pressure measurements, 
assessment of lipid and glucose metabolism, 
and electrocardiography, with effort testing 
where indicated. Treatment of these risk 
factors contributes to a decreased risk of 
incident myocardial infarction, stroke and 
arrhythmias – the major causes of mortality 
in COPD.[9] Obstructive sleep apnoea is an 
increasingly common condition, adding to 
baseline risk, and questionnaires such as the 
Epworth sleepiness scale[10] may be used to 
assess risk and determine referral for sleep 
evaluation.
Psychiatric comorbidity and psychosocial 
stressors influence patient behaviour, particularly 
regarding smoking cessation. The presence of a 
major depressive disorder decreases continued 
abstinence rates.[11] Furthermore, psychiatric 
conditions are prevalent in COPD, as in most 
chronic disorders, and if left untreated might 
lead to decreased compliance with management 
and reduced quality of life.[12] 
Osteoporosis screening should be done 
in male and female patients with increased 
risk, especially if they still smoke. COPD 
contributes to overall fracture risk, and 
fractures increase long-term morbidity and 
mortality.[13] It is therefore essential that this 
frequently overlooked risk factor is evaluated 
and managed appropriately.
Conclusion
A diagnosis of COPD should be suspected in 
patients who present with slowly progressive 
shortness of breath, even without a history 
of smoking. Take a detailed history of 
exposure to tobacco, dagga, methaqualone 
and other environmental pollutants. 
Document the history of exacerbations and 
identify other comorbid diseases. Clinical 
examination is helpful to support the 
diagnosis and rule out other respiratory 
conditions. Spirometry/lung function tests 
(pre- and post-FEV1 and FVC) are required 
to confirm the diagnosis and aid in severity 
grading. Radiology is often supportive but 
not a prerequisite, unless one is screening 
for lung cancer, and other specialised tests 
are generally not needed. With this holistic 
evaluation in place, appropriate decisions 
on management can be taken. Where 
symptoms and signs do not match, the 
disease progression is rapid, or in young 
patients referral to a specialist may be 
needed to exclude another unrecognised 
pulmonary condition. 
References
1. Global Initiative for Chronic Obstructive Lung Disease 
(GOLD). Global Strategy for Diagnosis, Management 
and Prevention of COPD. 2015. http://www.goldcopd.org 
(accessed 24 July 2015).
2. World Health Organization. The Global Burden of Disease: 2004 
update. Geneva: WHO, 2008.
3. Buist AS, McBurnie MA, Vollmer WM, et al. International 
variation in the prevalence of COPD (the BOLD Study): A 
population-based prevalence study. Lancet 2007;370(9589):741-
750.
4. GINA-GOLD. Diagnosis of diseases of chronic airflow 
limitation: Asthma, COPD and asthma-COPD overlap 
syndrome (ACOS). 2014. http://www.goldcopd.org/asthma-
copd-overlap.html (accessed 24 July 2015).
5. Abdool-Gaffar MS, Ambaram A, Ainslie GM, et al. Guideline 
for the management of chronic obstructive pulmonary disease 
– 2011 update. S Afr Med J 2011;101(1):61-73.
6. Koegelenberg CF, Swart F, Irusen EM. Guideline for office 
spirometry in adults, 2012. S Afr Med J 2013;103(1):52-62. 
[http://dx.doi.org/10.7196/samj.6197]
7. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator 
responsiveness in patients with COPD. Eur Respir J 2008;31(4):742-
750. [http://dx.doi.org/10.1183/09031936.00129607]
8. COPD assessment test. http://www.catestonline.org (accessed 
24 July 2015).
9. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel 
discontinuation after acute coronary syndromes: Frequency, 
predictors and associations with death and myocardial 
infarction – a hospital registry-primary care linked cohort 
(MINAP-GPRD). Eur Heart J 2011;32(19):2376-2386.
10. Epworth sleepiness scale. http://yoursleep.aasmnet.org/pdf/
Epworth.pdf (accessed 24 July 2015).
11. Prochaska JJ. Smoking and mental illness – breaking the link. 
N Engl J Med 2011;365(3):196-198. [http://dx.doi.org/10.1056/
NEJMp1105248]
12. Hanania NA, Mullerova H, Locantore NW, et al. Determinants 
of depression in the ECLIPSE chronic obstructive pulmonary 
disease cohort. Am J Respir Crit Care Med 2011;183(5):604-611. 
[http://dx.doi.org/10.1164/rccm.201003-0472OC]
13. Romme EA, Geusens P, Lems WF, et al. Fracture 
prevention in COPD patients; a clinical 5-step approach. 
Respir Res 2015;16:32. [http://dx.doi.org/10.1186/s12931-
015-0192-8]
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